Thymoenzym 2G

INMUNOMODULATOR BY INDUCTION

Thymoenzym regulates, compensates, fortifies, and boosts the body’s defences, by stimulating haematopoietic and erythropoietic action.

The immune system booster par excellence, it is the treatment most widely used in Europe in patients with auto-immune diseases, such as rheumatoid arthritis, psoriasis, lupus, etc.

Thymoenzym increases local and general immune responses, as manifested through the rapid elimination of infectious (viral, bacterial, mycotic) agents and the elimination of the pathology from the organ.  The latter is evidenced, for example, by an improvement in liver function in cases of chronic hepatitis, or functional improvement of the peripheral nervous system in cases of polyneuropathy.

Sustained immunological effect, with no side effects. Safe.

• Maximum therapeutic safety and effectiveness.
• Satisfactory cost/health ratio.
• Flexible dosage. Available in two forms: Injectable 500 mg and oral 250 mg, therebyfacilitating treatment.
• Immune system boosting therapy. Deep-acting second-line treatment for auto-immune diseases.
• Fast immune response action.

What are the symptoms of auto-immune diseases?
         *Constant bouts of flu
         *Recurring illnesses and general malaise
         *Deficient blood markers
         *Joint pain
         *Physical exhaustion

What can be expected from this treatment and what benefits are obtained?
Thymoenzym is essentially an immunological product which supports the action of the components of the defence system; therefore, its action is slow and progressive, but effective.

During the first thirty days of treatment, positive results will be noted, such as:

• Diminished recurrence of infectious diseases.
  
• Improvement in haematological indices.
  
• Diminished symptoms in cases of rheumatoid arthritis.
  
• Increased energy.

What does Thymoenzym contain?
Thymoenzym contains thymus extract and the peptides thereof, superoxide dismutase (SOD), catalase and glutathione, which make up, as a whole, the most complete and effective formula for the treatment of immunological deficiencies.

How long before effect is noted?
Being a treatment for different diseases which affect very important functional areas, results vary. Generally, an improvement is noted after 30 days of commencing treatment. As with all therapies, consistency in administration is required.

CLINICAL INFORMATION AND PHARMACOLOGY

Composition:

Each injectable vial contains 500 mg and each tablet contains 250 mg of total thymus extract, in addition to an enzymatic formula composed of adenosine deaminase, superoxide dismutase, glutathione reductase, glutathione-S-transferase, and glutathione peroxidase. Amino acid preparation composed of: isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan, threonine, and valine. Natural extracts of: panax ginseng, tecoma curialis.

Mechanism of Action:
Thymoenzym’s components activate all immune defence mechanisms.  Thymoenzym consolidates the action of T cells, which are essential for proper functioning of the immune system.

PHARMACOKINETICS
The tablet dissolves completely when it comes into contact with the basic pH of the small intestine; this protects the enzymes present in the formula, which act at a near-basic pH. Once released, the main active ingredients (enzymes, thymus extract, amino acids and components of the natural extracts) are absorbed in the proximal part of the small intestine and a small amount is absorbed in the distal part of the jejunum. They are then incorporated into the bloodstream, where activation commences of the immunobiological processes: enzymatic action on related substrates, cell penetration of amino acids by active transport or facilitated by the participation thereof in the “amino acid pool,” stimulation and “wakening” of thymus function to boost the immune system.

In the case of injectable Thymoenzym, after administration thereof, the main active ingredients are absorbed directly into the bloodstream. This absorption takes place by simple diffusion following the gradient which exists between the deposit of the main active ingredients and the plasma. There is a rapid speed of absorption, since the area of the capillary membranes which absorb the product is broad and these are very soluble in the interstitial fluid. The relatively large aqueous channels of the endothelial membrane allow a high rate of diffusion of these molecules, regardless of their liposolubility. Distribution is to all the body’s tissues, but mainly to the liver (50%) where some amino acids are stored, after a first-step metabolism. Metabolites are eliminated through the urine and faeces.

Indications and Dosage:
Below, by way of example and based on broad clinical experience, we show some therapeutic recommended uses in the following areas of specialisation. However, it is up to the physician’s discretion to decide which dosage and which therapeutic plan he will use, according to each specific case and pathology. 
The clinical experience which this research has yielded supports the combined use thereof with other medications, since the coadjutant and boosting actions prove the preventative efficacy of THYMOENZYM, which does not interact with any other treatment.

Indications by Specialisation, Dose, Frequency and Administration of the Treatment.

Internal Medicine, Immunology.

Immune System Disorders:
Primary: The initial recommended dosage is to inject one full dose of one (1) vial of Thymoenzym 500 mg every other day for 20 days, for a total of 10 injections; this treatment should be administered together with 4 tablets of Thymoenzym Oral 250 mg twice a day (4 b.i.d.) (morning and evening) before meals, taken daily for 60 consecutive days. After the first 2 months of initial treatment have concluded, it is recommended that the patient be clinically evaluated monthly to ascertain whether to continue or discontinue the treatment, as per the physician’s discretion. Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in his/her symptoms.

Rheumatoid Arthritis: The initial recommended dosage is to inject one full dose of one (1) vial of Thymoenzym 500 mg every other day for 20 days, for a total of 10 injections; this treatment should be administered together with 4 tablets of Thymoenzym Oral 250 mg twice a day (4 b.i.d.) (morning and evening) before meals, taken daily for 60 consecutive days. After the first 2 months of initial treatment have concluded, it is recommended that the patient be clinically evaluated monthly to ascertain whether to continue or discontinue the treatment, as per the physician’s discretion. Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in his/her symptoms.

AIDS: The initial recommended dosage is to inject one full dose of one (1) vial of Thymoenzym 500 mg daily for 30 consecutive days, for a total of 30 injections; this treatment should be administered together with 4 tablets of Thymoenzym Oral 250 mg twice a day (4 b.i.d.) (morning and evening), taken daily before meals. Patient should be clinically evaluated monthly, checking his/her T4 levels, to ascertain whether to modify or maintain the treatment, as per the physician’s discretion.
Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in his/her symptoms.

Post-chemotherapy: The initial recommended dosage is to inject one full dose of one (1) vial of Thymoenzym 500 mg daily for 60 consecutive days, for a total of 60 injections; this treatment should be administered together with 4 tablets of Thymoenzym Oral 250 mg twice a day (4 b.i.d.) (morning and evening), taken daily before meals. Patient should be clinically evaluated every 15 days to ascertain whether to modify or maintain this treatment, as per the physician’s discretion.
Results: Once the first stages of the treatment have elapsed, an improvement in values and of the immune system should be noted.

Hypoglobulinemia: The initial recommended dosage is to inject one full dose of one (1) vial of Thymoenzym 500 mg daily for 30 consecutive days, for a total of 30 injections; this treatment should be administered together with 4 tablets of Thymoenzym Oral 250 mg twice a day (4 b.i.d.) (morning and evening), taken daily for 30 days. Subsequently, treatment should be continued but decreasing the frequency, injecting one dose of Thymoenzym 500 mg twice a week (every 3 days) for 30 days, for a total of 10 injections, together with 2 tablets of Thymoenzym Oral twice a day (2 b.i.d.) (morning and evening) before meals, taken daily for 30 consecutive days. Patient should be clinically evaluated monthly, checking his/her blood levels, to ascertain whether to modify or maintain the treatment, as per the physician’s discretion.
Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in his/her symptoms.

Down’s Syndrome: The initial recommended dosage is to inject a half-dose of 2.5 ml of Thymoenzym 500 mg every other day for two months, for a total of  30 injections; this treatment should be administered together with 2 tablets of Thymoenzym Oral 250 mg twice a day (2 b.i.d.) taken daily (morning and evening) before meals.  Patient should be clinically evaluated monthly to ascertain whether to modify or maintain the treatment, as per the physician’s discretion.
Results: Once the first stages of the treatment have elapsed, the patient should experience an improvement in his/her response to related infections.

Oncology:
Soft cancers: The initial recommended dosage is to inject one full dose of one (1) vial of Thymoenzym 500 mg every other day for 180 days, for an approximate total of 100 injections; this treatment should be administered together with 4 tablets of Thymoenzym Oral 250 mg twice a day (4 b.i.d.) (morning and evening), taken daily before meals.  Patient should be clinically evaluated monthly to ascertain whether to modify or maintain the treatment, as per the physician’s discretion.
Results: Once the first stages of the treatment have elapsed, a substantial improvement in the patient’s immune response should be noted.

Preventative Treatments to Boost and Improve the Immune System:

Preventative Treatment #1
The initial recommended dosage is to inject one full dose of one (1) 5-ml vial of Thymoenzym 500 mg daily for 10 consecutive days; subsequently to this treatment, Thymoenzym Oral 250 mg can be administered for three months, taking 2 tablets daily (1 b.i.d.) in the morning and in the evening, before meals.

Preventative Treatment # 2
Two tablets daily of Thymoenzym Oral 250 mg (1 b.i.d.) morning and evening (60 tablets monthly) for 7 consecutive months.

Preventative Treatment #3
The combined use is recommended of Thymoenzym Injectable 500 mg twice a week (at intervals of at least 72 hours) for a period of two months, for an approximate total of 16 injections, together with Thymoenzym Oral 250 mg, alternating monthly with Bioenzym, for example, if it is necessary to boost organic defences or against degenerative diseases. The combined use of Thymoenzym and Bioenzym boosts and strengthens the treatment, indicating two tablets daily of Thymoenzym Oral 250 mg twice a day (2 b.i.d.) and two tablets daily of Bioenzym twice a day (2 b.i.d.), in both cases before meals.

Analysis:  Thymoenzym increases local and general immune responses of natural origin, replacing the action of the thymus gland in the human being, which disappears almost completely with age. The same as with all replacement therapies, Thymoenzym has excellent tolerance both for immunoprophylaxis as well as for immunological intervention in the body.

Contraindications:  Internal bleeding after or during treatment with cortisone or other suprarenal gland derivative products. In this last case, 6 weeks should be waited before commencing treatment. In the case of pregnancy, it can be administered after the first trimester. During treatment, products containing acetylsalicylic acid (aspirin) cannot be taken.   

Side Effects: After the first injections, local pruritis or reddening may occur; this does not happen when taking Thymoenzym in oral form. In the case of the injectable form, a cream containing heparinoid may be used. There may also be a rise in body temperature or fever, which should disappear within 2 to 4 hours. No major reactions have been observed.

Administration: Thymoenzym should be injected IM in the buttocks area, slowly.  It is recommended that it not be injected after ingesting food, preferably waiting 2 hours after meals to administer it. A half-dose of 2.5 ml or one (1) full dose of 5 ml may be administered daily, up to a maximum of 3 full doses per day, with no contraindications.

SUMMARY OF CLINICAL STUDY:

STUDIES ON NATURAL CYTOTOXICITY OF HUMAN MONOCYTES IN VIRAL  HEPATITIS

Blackwell, S, Summer, T.

Studies were conducted on the natural cytotoxicity of peripheral blood monocytes in patients with acute viral hepatitis B, patients with chronic aggressive hepatitis linked etiopathogenically to viral hepatitis B and in asymptomatic HB antigen carriers. In most cases of acute vital hepatitis and in those of chronic aggressive hepatitis, a significant reduction in the monocyte function examined was noted, which normalised during the convalescence period.  The results obtained with HB antigen carriers did not differ from those obtained in normal blood donors.  The observations made may indicate that the restriction of the natural cytotoxicity of monocytes during the evolution of viral hepatitis B is related to a hepatic lesion. The disturbance of the natural monocytic cytotoxicity returned to normal during incubation in vitro with THYMOENZYM.

Bibliography:

• Hall, N.R., et al. (1985): Evidence that thymosins and other biologic response modifiers can function as neuroactive immunotransmittere. J. Immunol, 135: 806.  
• Haritos, A. A., et al. (1984): Prothymosin : Isolation and Properties of the Major Immunoreactive Form of Thymosin 1 in Rat Thymus. PNAS  81: 1008.
• Jevremovic, M. (1989): Neuroendrocrine oxytocic activity of human fetal thymus. J. Reproduct. Immunol. Suppl. 1:198.
• Kendall, M.D. (1988): Microenvironment of the Human Thymus (Thymus Update Series). Harwood Academic Publishers.
• Maggi, M., et al. (1987): Identification and characterization of two classes of receptors for oxytocin and vasopressin in porcine tunica albuginea, epididymis and vas deferens.  Endocrinology 120: 986- 994.